Protalix jumps on FDA nod for genetic disorder therapy

Protalix BioTherapeutics

10/05/2023 11:33

** U.S.-listed shares of Israeli drug developer Protalix
Biotherapeutics Inc  PLX.N  rise 18.5% to $3.46 premarket
    ** U.S. FDA has approved PLX and partner Chiesi Global Rare
Diseases' experimental therapy to treat adult patients with
Fabry disease, Protalix says
    ** The therapy, Elfabrio, replaces an enzyme which causes
abnormal deposits of a type of fat in blood vessels and tissues
- PLX
    ** Fabry disease is a rare genetic disorder that could
eventually lead to kidney failure, heart failure and stroke
    ** Up to last close, U.S.-listed shares of Protalix have
more than doubled so far this year
    

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))